vary from one study to another, they show generally a lower risk of relapse, and a longer disease-free survival (DFS) after AlloBMT and ABMT than after ICC. A cross-sectional study of quality of life (QOL) was performed in 98 patients in continued first complete From 1986 to 1992, the EORTC and GIMEMA Leukemia Cooperative Groups prospectively compared these remission (CR) for 1-7.4 years, after inclusion in the AML 8A trial which prospectively compared allogeneic three therapeutic options: patients with newly diagnosed AML were entered in the AML 8A trial, and, after the same bone marrow transplantation (AlloBMT), autologous BMT (ABMT) and intensive consolidation chemoinduction and intensive consolidation course, were assigned, according to availability of a family HLAtherapy. Several significant differences between the three treatment groups were observed, on the basis of matched donor or randomization, to AlloBMT, ABMT or a second ICC course. At a median follow-up time of 3.3 patient self-reports, with regard to somatic symptoms (mouth sores, cough, hair loss, headache), repeated years, there was a significantly longer DFS in the AlloBMT (55%) and ABMT (48%) arms than in the ICC arm (30%).
various components of these domains. 10 It is generally evaluation was performed from January 1993 to March assumed that self-report questionnaires are more reliable 1995. All eligible patients received a set of questionnaires than proxy evaluations.
11 Specific instruments may allow from their local investigator with a covering letter guaranbetter evaluation of the impact of treatments, and are usuteeing strict confidentiality and suggesting they contact a ally preferred to generic questionnaires. In addition, translocally appointed person in case of any problem. Medical cultural problems must be adequately solved, in order to information, especially that related to treatment sideprovide acceptable questionnaires to patients enrolled in effects, eg acute and chronic GVHD, was collected from international trials. 12 We decided, therefore, to perform a the case report forms filled in by the responsible physicians. cross-sectional study using the EORTC Quality of Life
The patient self-administered questionnaires included a Questionnaire (QLQ-C30) combined with specific modules demographic questionnaire, the EORT QLQ-C30 designed to assess QOL after treatment of acute leukemia questionnaire, a Leukemia-BMT-specific module, a short including BMT.
questionnaire on sexual functioning and fertility, and a questionnaire on patient perception of changes in the various domains of QOL (ie disease-related modifications).
Patients and methods
The demographic questionnaire was derived from Hollingshead. 13 Patients were also asked to indicate their mariPatients tal and employment status both pre-diagnosis and at the present time. Patients were eligible for the QOL study if they had been
The EORTC QLQ-C30 is a 30 item questionnaire which enrolled in the EORTC-GIMEMA AML 8A trial and were has been developed to cover a wide range of cancers, and in continued first CR 1 year or more after completion of is expected to be combined, for each study, with a diseasethe treatment protocol. The main inclusion criteria in the and/or treatment-specific module. 14 It includes five multitrial were: a diagnosis of AML in previously untreated item functional scales (Physical, Role, Cognitive, patients, and absence of severe concomitant disease.
Emotional and Social functioning), several single item Patients had to be more than 10 and less than 60 years old, symptom measures and two items for global assessment of but 25 patients (2.7%) were less than 15 and are not the overall physical condition and of QOL. Combination of included in the present study. Of the 623 patients from 59 the perceived Overall Physical Condition and Overall Qualcenters who achieved CR after the induction regimen, 576 ity of Life results in a Global Health Status score. This received a first ICC. Of them 168 patients had an HLAquestionnaire meets acceptable standards for reliability, and identical sibling and 144 underwent an AlloBMT. Two its external validity has been checked in several hundreds hundred and fifty-four patients were randomized to ABMT of patients with lung cancer, 14 and various types of canor second ICC, which were completed in 95 and 104 cer. 15 Its psychometric properties have been also evaluated patients, respectively. Eighteen centers agreed to participate in 125 adults surviving several years after BMT, 16 with a in the QOL study. Out of 155 patients from these centers high internal consistency, and good reliability of the Role, who were alive and in first CR for 1 year or more at the Emotional and Cognitive functioning scales, and of the time of study, 98 (63%) agreed to enter the QOL study : 35 Global Health Status. had an AlloBMT, 29 an ABMT, while 34 received only
The Leukemia-BMT module (QLQ-LEU-BMT) is a 32 chemotherapy.
item questionnaire which was designed on the basis of the known late side-effects of BMT in adult patients treated for Methods leukemia. Most of the items explore somatic symptoms, especially those currently experienced by patients suffering Informed consent was required for the QOL study, accordfrom GVHD. The psychometric properties of this module ing to local rules. The allocated anti-leukemic treatments received by these patients are shown in Table 1 . The QOL were analyzed in 388 patients entered into the present EORTC-GIMEMA AML 8A trial and into the MRC AML the QOL assessments (ie questions having as possible answers ordered categories) were tested using the Kruskal-10 trial in the UK, and who were in CR for at least 1 year after completion of treatment.
17 All 32 variables had indiWallis test. 19 The treatment comparisons leading to significant differences were adjusted a posteriori by some varividual measures of sampling adequacy greater than 0.5. Item total correlations and Cronbach alpha coefficients ables having a possible impact on QOL. For this purpose, the following categorized variables were considered for the indicate good internal consistency, many items being grouped into two subscales (alpha coefficients 0.79 and bi-variate analyses: sex (male vs female), age (Ͻ46 years vs у46 years), time from CR to the evaluation of QOL 0.71), which appear to correspond to GVHD and infection, respectively.
(Ͻ3 years, 3-4 years, у5 years). In case of ordered outcomes (overall physical condition, quality of life or global Most items of the EORTC QLQ-C30 and the QLQ-LEU-BMT use a 4-point Likert scale from 1 (not at all) to 4 health status -see below), the stratified generalized GehanWilcoxon test was used, 19 whereas for all other ordered (very much); overall physical condition and QOL were assessed by two 7-point Likert scales. In addition, the first outcomes ('not at all', 'a little', 'quite', 'much' or 'increased', 'same', 'decreased' or 'absent', 'present'), which were seven items of the EORTC QLQ-C30 correspond to two Guttman scales with dichotomous response categories (yes categorized as binary outcomes, the usual stratified 2 test 18 was used. The Global Health Status score (grading from or no).
Sexual disorders categorized according to the Diagnostic 0 to 100) has been constructed from the Overall Physical Condition (1-7) and Overall Quality of Life (1-7) using and Statistical Manual of Mental Disorder (DSM IV) were divided into problems of sexual drive (interest), sexual the recommendations of the EORTC QOL Study Group.
20
The Goodman-Kruskal ␥ coefficient 18 was used to measure arousal, orgasm disorder and pain disorder (eg dyspareunia). Four study specific single-item questions the association between these two last scales. The Kendall's test 18 was used to measure the relationship between asked about: (1) interest, (2) pleasure or satisfaction, (3) level of sexual activity and, (4) ability to engage in patient characteristics and the QOL items. The planned sample size for the QOL study was 135 (45 sexual intercourse since their leukemia treatment (ie increased, decreased or remained the same). Level of pain patients for each treatment group), as quite large differences between the treatment groups in terms of side-effects and during sexual intercourse was also assessed by one item from the Leukemia-BMT module on a 4-point scale ranging QOL were expected. For instance, 30% difference (20 vs 50%) between two treatment groups regarding the occurfrom 'not at all' to 'very much', with a high score indicating more of a problem. Problems with fertility were rence of side-effects requires a total of 90 patients (alpha = 0.05, beta = 0.20). However, due to administrative assessed by study-specific items; patients were asked if their treatment had caused infertility and, in those indicatdifficulties, the QOL assessment was implemented in only 18 out of 59 centers which participated in the AML 8A ing that it had, if they had been aware of the possibility of infertility at the time they were initially treated. The extent study. Therefore, the reported P values should be considered cautiously: due to a relative low statistical power to which they were bothered by infertility was assessed by a 7-point rating scale ranging from 'not at all' to 'very for detection of moderate treatment differences (range 20-30%), a result which yields a P value Ͼ0.05 does not necesmuch'. Those who reported that they considered themselves rendered infertile by the treatment were asked if they were sarily mean that treatment impact on QOL is negligible. Conversely, due to the multiple comparisons, a P value seeking a resolution to their infertility (eg adoption, artificial insemination by donor) and whether this had been which is significant according to the classical rule (р0.05), does not necessarily mean that one may reject with full successful.
Finally the questionnaire included a Disease-Related confidence the null hypothesis (no treatment difference), as the risk of a false positive result is high in this instance. Modifications module, where patients were asked to evaluate the changes induced by their disease and treatment on several domains, each covered by a single item (Energy, Mood, Intellectual Capacity, Family Life, Sexual RelationResults ship, Professional Life, Social Relationships, Leisure Activities and Quality of Life) with a 5 point scale of
The QOL study was performed at a median time of 53 months after achievement of CR (range 12-89 months). changes, ranging from 'far worse' to 'far better'.
All these questionnaires, first developed in English, were The characteristics of the patients at the time of QOL evaluation are shown in Table 2 . There are slight differences translated into four European languages, French, Dutch, German, Italian, using a 'forward-backward' translation between the three treatment groups, but only the difference for age at time of QOL evaluation was significant ( 2 test; procedure. The reliability and validity of the EORTC QLQ-C30 is highly consistent across the three language-cultural P = 0.05). This is explained by the fact that in some participating centers the upper age limit for randomization groups studied: patients from English-speaking countries, Northern Europe and Southern Europe. 14 between ABMT and ICC was 60, whereas for AlloBMT the age limit of 45 was kept more often. The time elapsed between achievement of CR and evaluation of QOL was Statistical methods similar in the three treatment groups.
Patients included in the QOL study differed significantly The usual 2 test 18 with the correction for continuity was used to test the balance of the initial characteristics among from those who were not included, despite a similar DFS, with regards to age (a higher proportion above 46 years), the treatment groups. The treatment differences regarding Table 2 Patients' characteristics at time of quality of life evaluation sex (more males), treatment completion (less premature with the QLQ-LEU-BMT. Table 4 shows those items for which differences were significant. For all those items stop for toxicity or refusal), and proportion of randomized patients (higher). However, they were not different with except two ('taking pills/medicine or having seen a doctor during the last month') the same ranking was observed regards to response to the first induction course, to balance between the randomized arms, and to incidence and grade regarding the frequency/severity of problems, being higher in the AlloBMT group, compared with the ABMT group, of acute or chronic GVHD.
both of which were higher than in the chemotherapy group. There was no significant difference between the treatment EORTC QLQ-C30 questionnaire groups for the other items, although a trend with the same ranking was observed for chills, changes in appearance, eye Significant differences were observed between the treatment groups for items evaluating physical functioning ('Do dryness, and skin dryness (Table 5) . Some items of the QOL-LEU-BMT module correlated you have any trouble in taking a long walk?') and role functioning ('Are you limited in any way in doing either significantly with the use (50 cases) or not (14 cases) of TBI during the conditioning regimen for AlloBMT or your work or doing household jobs?') ( Table 3) . Differences for the other items and scales assessing cognitive, ABMT (eye dryness: TBI (65%) vs no TBI (7%), P = 0.011, and headache: TBI (54%) vs no TBI (29%), emotional and social functioning were not significant. The overall physical condition and quality of life were signifi-P = 0.05). On the other hand mouth sores correlated with the occurrence and grade of chronic GVHD (no GVHD: cantly different between the three treatment groups with mean scores for AlloBMT Ͻ ABMT Ͻ chemotherapy. The 1/13 (8%); mild GVHD: 5/11 (45%), moderate/severe GVHD: 6/11 (55%) P = 0.01). resulting mean global health status on a 0-100 scale was therefore about 70 for AlloBMT, 75 for ABMT and 80 for chemotherapy. Of note, a high association was observed Sexuality-Fertility between overall physical condition and overall QOL (Goodman-Kruskal ␥ = 0.70, P Ͻ 0.001). More often (26
The main results for sexual functioning are shown in Table  6 . Sexual functioning was impaired in about one third of cases), patients rated their QOL as being higher than their physical condition, than the reverse (15 cases).
patients and was significantly more frequently impaired after AlloBMT (47-68% according to the items) than after ABMT (18-30%) or chemotherapy (15-22%). In addition, Leukemia-BMT module there was significantly more pain during sexual intercourse in patients treated by both BMT procedures (Table 4) . Although the somatic items included in the EORTC QLQ-C30 were not significantly different between the treatment Patients who received TBI had impaired sexuality more often than those not receiving TBI, but none of the comgroups (especially those relating to pain, nausea/vomiting, lack of appetite, fatigue), several differences were observed parisons reached statistical significance, probably due to an Data with a trend, and a ranking consistent with the other results, are labelled in bold characters. insufficient number of patients. Moreover, in the 35 patients overall QOL, their present status with their pre-disease status. It can be seen that a wide range of perceived changes who underwent AlloBMT, while the grade of acute GVHD seems to be associated with impaired sexuality, the grade was reported by patients, from 'far worse' to 'far better'. However, there was a trend in reporting the present status of chronic GVHD did not correlate with the results of the Sexuality module.
as being worse rather than better. When the three treatment groups were compared, a worsening was significantly more Treatment-related infertility was reported by 63, 48 and 3% of patients who underwent AlloBMT, ABMT and frequently reported for leisure activities after AlloBMT or ABMT than after chemotherapy. There was also a trend chemotherapy, respectively, while 3, 14 and 32% of them in each treatment group declared themselves not to be infertowards a worsening in AlloBMT and ABMT groups with regards to sexual relationship and mood. A worsening of tile, and the remaining patients did not know their status in this regard (overall 2 ; P Ͻ 0.001). Most of the BMT the overall QOL was reported by 51% of patients who underwent AlloBMT, vs 38% of ABMT patients and 30% patients said they had been informed about the risk of infertility at time of allocation of treatment (20, 62 and 83% in of the ICC patients, but the difference was not statistically significant. the three treatment groups, respectively). Only three patients looked for a resolution to their infertility, with only one male patient treated by ABMT being successful through the use of cryopreserved sperm. There was no Discussion significant difference between the three treatment groups when patients were asked whether they were bothered by Our study shows some significant differences between AlloBMT, ABMT and chemotherapy, when assessing the infertility.
long-term side-effects and multiple dimensions of QOL. These relate to somatic side-effects such as mouth sores, Treatment adjustment and prognostic factors cough, headache, hair loss, and frequent acute episodes leading to referral to physicians. The most important longAfter adjustment for sex as well as age at time of evaluation, the evaluation of differences between the treatment term side-effects reported by patients were, however, infertility, decrease of sexual activity and loss of libido. These groups led to similar results to those presented in Table 3 . In addition, the treatment comparisons yielded similar consequences of treatment consolidation of AML were more frequently observed after AlloBMT, and, to a lesser results after adjustment for time interval between achieving CR and evaluation of QOL. For most items, there was no degree, after ABMT, than after chemotherapy. The same ranking was observed, using the EORTC QOL core questrend towards improvement as this time interval increased, except for mouth sores which tended to be more frequently tionnaire, for physical and role functionings, with more limitations in physical and work performances in patients observed in patients studied within the first 3 years after achieving CR. Furthermore, sexual problems were more who had received AlloBMT. This ranking was consistent for most comparisons, giving more strength to the statistical frequently reported by females, who more often indicated a decrease of interest in sex (46 vs 25%, P = 0.021), and comparisons, despite the caveat emphasized in the Methods section. Although our study was based on an empirical in older patients (ie 46 years and above) who reported less sexual pleasure than younger patients (70 vs 25%, analysis through the main domains of QOL, most results correspond to what was expected from the known toxicity P = 0.016).
of the compared treatment modalities. Several studies have been published recently on various Perceived changes by the patients aspects of QOL in adults surviving after BMT. [6] [7] [8] [9] 16, [21] [22] [23] [24] [25] [26] [27] [28] Except for one prospective study, 9 they were cross- Table 7 shows the changes perceived by patients when asked to compare, for the main domains of QOL, and the sectional analyses from 6-12 months and up to 18 years, 16 after completion of BMT. Transplantation procedures perual patients to make a decision, after taking into consideration the relative risks of relapse and treatment-related morformed included AlloBMT only, or combined AlloBMT, syngeneic BMT, and ABMT groups, while two studies tality. In addition, patient rating of their own QOL was more frequently better than their rating of overall physical focused on ABMT, in patients mainly treated for lymphoid malignancies.
29, 30 Usually these publications included a condition and there was no significant change in the perceived global post-treatment QOL. These results might variety of diseases. Few studies were intended to compare BMT and chemotherapy. 22, 23, 29 Only one was specific for indicate that the majority of patients adapt their perception of QOL, despite post-treatment somatic sequelae, but could AML, and compared AlloBMT and intensive consolidation chemotherapy, for patients included in two consecutive proalso be related to a lack of sensitivity of global QOL scale in picking up specific problems. spective trials. 25 Our study is, therefore, the first which evaluates specifically the long-term QOL of AML patients
The most important difference between the treatment groups was related to sexual functioning and psychosexual included in a multicenter international prospective trial comparing AlloBMT, ABMT and intensive chemotherapy.
sequelae. Although our Sexuality-Fertility module was quite simple and brief, and deserves further validation, the Although not all participating centers and eligible patients of the AML 8A trial collaborated in the QOL study, the data indicate a significantly greater impairment after AlloBMT and, to a lesser degree, after ABMT than after number of patients, centers and countries represented makes a selection bias unlikely.
CT. These differences correlated with infertility which resulted from BMT. Sexual dysfunction has been highMost of the previous publications have emphasized a normal or near normal QOL in the vast majority of patients lighted by two important studies dealing with problems in long-term survivors after AlloBMT. 16, 24 Surprisingly, other treated by AlloBMT, after some emotional and social adjustment. 7, 31 A high prevalence of depression was authors have not found differences with regards to psychosexual functioning in patients treated by AlloBMT or observed by Jenkins et al, 8 especially in patients with antecedent psychiatric disorders, with no difference between CT. 25, 33 However, as shown by several other analyses focused on both psychosexual, hormonal and fertility AlloBMT and ABMT. However, several studies have pointed out the possibility of long-term physical, psychoaspects [34] [35] [36] [37] [38] sexual dysfunction is likely to occur in patients with sexual organ failure due to conditioning with intensive logical or social problems after BMT. Permanent fatigue and lack of energy/stamina are frequently reported. 6, 7, 16 chemotherapy or radio-chemotherapy. 39 One can hypothesize several factors to explain the higher Cognitive dysfunction has been also observed, 16 which might be related to the dose of TBI. 32 Although most of frequency of sexual dysfunction after BMT -especially AlloBMT -such as the use of TBI during conditioning, or these young adult patients return to work, have good social support, and keep or restore satisfying family/partner the occurrence of acute GVHD. We did not observe significant correlations with these factors, perhaps due to the relationships, unemployment, financial and marital problems have been reported in a substantial prorelatively limited number of patients in each group. Further studies are required, to identify the etiological factors (eg portion. 7, 9, 24, 26, 28 The risk of job discrimination and problems in obtaining insurance have also been emphasized. 26 impact of dosage in TBI on gonadal function). Of note, some predictive variables have already been reported to Comparison of AlloBMT with alternative treatments yielded controversial results: Lesko et al, 22 Litwins et al, 23 influence sexual satisfaction of long-term survivors such as a younger age at time of transplant, overall life satisfaction and Wellisch et al 25 failed to observe differences between BMT and CT with regard to various domains of QOL, and satisfying relationship with spouse or partner. 39 However, hormonal failure is likely to be the most important whereas Altmaier et al 28 found more physical symptoms, unemployment, financial and marital problems in BMT etiological factor, and along with infertility, represents an important part of an eventual permanent impairment of than in matched CT patients. 28 However these comparisons were based on small patient numbers, and, except for one, 25 QOL after BMT. Several measures are available to treat these long-term side-effects such as cryopreservation of were performed outside prospective trials.
Despite the limited number of patients in each treatment sperm or ova, and hormonal replacement. For other patients, who, for individual preference, would not accept group, our results indicate differences which consistently confirm the same ranking: AlloBMT Ͻ ABMT Ͻ CT, most the risk of these permanent side-effects, another possible solution is to give preference to ICC consolidation during CT patients being treated with high-dose Ara-C consolidation courses. These differences were found for physical first CR, and to choose BMT only as a salvage treatment in case of relapse. symptoms, role functioning, leisure activities, and, especially, for sexual functioning. Probably as a conseSome studies have identified, through multivariate analyses, variables which might represent risk factors for impairquence, using the EORTC-QLQ C30 questionnaire, significant differences with the same ranking were observed ment of QOL after BMT, especially TBI, GVHD, age, education level, role retention, and social support. 40 If between the three treatment modalities for overall physical condition, overall QOL, and the resulting global health confirmed, these factors would indicate which appropriate medical and psychosocial measures are needed to preserve status. These differences must be viewed, however, in terms of relative weighting of the average scores: the differences or restore the QOL during and after such intensive treatments. For example, avoiding TBI during conditioning regibetween the less severe (ICC) and the more severe (AlloBMT) might appear small (10% for the global health men for AlloBMT and ABMT might be recommended, since in AML a pure chemotherapy regimen seems to yield status), not important enough to indicate that CT prevails. Therefore some caution is necessary when helping individequivalent DFS as a radio-chemotherapy regimen. 
